Business description
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on outlicensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
Management board & Supervisory board
| CEO |
| Oliver R. Baumann |
| Management board |
| Carl von Halem, Dr. Frank Plöger, Beat Kläui, Christian Faber |
| Supervisory board |
| Dr Bernhard Scholz, Mark S. Müller, Simon Schöni, Oliver R. Baumann, David L. Deck, Désirée Dosch, Dr. Norbert Windhab |
Company data
| Name: |
Xlife Sciences AG |
| Address: |
Klausstrasse 19,CH-8008 Zürich |
| Phone: |
+41-44385-8460 |
| Fax: |
- |
| E-mail: |
info@xlifesciences.ch
|
| Internet: |
https://www.xlifesciences.ch/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12-31 |
| Free Float: |
- |
| IPO date: |
- |
Investor relations
| Name: |
Elena Sachs |
| IR phone: |
+41-44385-8462 |
| IR Fax: |
- |
| IR e-mail: |
ir@xlifesciences.ch
|
